Matthew McManus - Feb 1, 2024 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role: President - DGS
Signature: /s/ Andrew Nick as Attorney-in-Fact for Matthew McManus pursuant to Power of Attorney previously filed.
Stock symbol: TECH
Transactions as of: Feb 1, 2024
Transactions value $: $0
Form type: 4
Date filed: 2/5/2024, 06:35 PM
Previous filing: Feb 5, 2024
Next filing: Feb 3, 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TECH	Restricted Stock Units	Award	$0	+2.89K		$0.00	2.89K	Feb 1, 2024	Common Stock	2.89K		Direct	F1, F2
transaction	TECH	Restricted Stock Units	Award	$0	+13.9K		$0.00	13.9K	Feb 1, 2024	Common Stock	13.9K		Direct	F1, F3
transaction	TECH	Stock Option (Right to Buy)	Award	$0	+7.95K		$0.00	7.95K	Feb 1, 2024	Common Stock	7.95K	$68.54	Direct	F2
transaction	TECH	Stock Option (Right to Buy)	Award	$0	+15.9K		$0.00	15.9K	Feb 1, 2024	Common Stock	15.9K	$68.54	Direct	F4

Showing 1 to 4 of 4 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F2	Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F3	4,620 restricted stock units vest on 2/1/2025 and 2/1/2027, and 4,621 restricted stock units vest on 2/1/2026.
F4	Options to purchase 3,976 shares vest on 2/1/2025 and 2/1/2027, and options to purchase 3,975 shares vest on 2/1/2026 and 2/1/2028.